Potential Benefits on Impairment of Endothelial Function after a High-Fat Meal of 4 Weeks of Flavonoid Supplementation by Barringer, T. A. et al.
Hindawi Publishing Corporation
Evidence-Based Complementaryand Alternative Medicine
Volume 2011, Article ID 796958, 6 pages
doi:10.1093/ecam/nen048
Original Article
PotentialBeneﬁtsonImpairmentof EndothelialFunctionafter
aHigh-FatMeal of4 Weeks ofFlavonoidSupplementation
T .A.B arringer ,L.H at c her,andH.C.Sasser
Center for Cardiovascular Health (TAB, LH) and Dickson Institute for Health Studies (HCS), Carolinas Healthcare System,
P. O. Box 32861, Charlotte, NC 28232, USA
Correspondence should be addressed to T. A. Barringer, tbarringer@carolinas.org
Received 20 September 2007; Accepted 30 May 2008
Copyright © 2011 T. A. Barringer et al.Thisisanopen accessarticledistributed undertheCreative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Studies with foods high in ﬂavonoids have demonstrated improvement in endothelial function. We investigated whether 4 weeks
of ﬂavonoid supplementation would prevent an adverse impact on endothelial function of a high-fat meal. Endothelial function
was measured by reactive hyperemia peripheral arterial tonometry (RH-PAT). The RH-PAT index was measured both before and
3 h after a high-fat meal, in 23 healthy volunteers. Subjects were randomized in a double-blind, cross-over design to 4 weeks of
daily supplementation with OPC-3, or a matching placebo. RH-PAT index before and after the high-fat meal was measured at the
beginning and end of each 4-week treatment phase. The high-fat meal caused a decline in endothelial function at baseline in the
placebo (−10.71%, P = .006) and ﬂavonoid [−9.97% (P = .077)] groups, and there was no diﬀerence in decline between arms
(P = .906). The high-fat meal produced a decline after 4 weeks of placebo [−12.37% (P = .005)], but no decline after 4 weeks
of ﬂavonoid supplement [−3.16% (P = .663)], and the diﬀerence between the two responses was highly signiﬁcant (P < .0001).
Within-groupcomparisonsrevealed nodiﬀerence inendothelialfunction decline in the placebo armbetween baseline and4 weeks
[−10.71% versus −12.37% (P = .758)]. In the ﬂavonoid supplement arm, the diﬀerence in endothelial function decline between
baseline and 4 weeks was −9.97% versus −3.16%, but did not reach statistical signiﬁcance (P = .451). These results suggest that
the ﬂavonoid supplement used in this study mitigates the impairment of endothelial function caused by a high-fat meal. Whether
certain subpopulations derive greater or lesser beneﬁt remains unclear.
1.Introduction
A high intake of fruit and vegetables has been associated
with a reduced risk for cardiovascular disease [1]. While
the exact mechanisms for this beneﬁt are unknown, there
is general consensus within the scientiﬁc literature that it is
at least partially derived from the antioxidant eﬀects of the
numerous polyphenols found in the diet [2–6]. In particular
various foods high in ﬂavonoids (e.g. tea, cocoa, wine, citrus
fruit) have been associated with lower risk for cardiovascular
disease in most, but not all, studies [7–11]. In order to deter-
mine the cause(s) of the epidemiological inconsistencies, as
well as to elucidate the mechanism by which foods high
in ﬂavonoids might exert a cardiovascular protective eﬀect,
further studies in humans and animals are needed. Most
importantly studies are needed using experimental designs
which reduce the variability of ﬂavonoid exposure. Such
variability is an inherent problem in epidemiologic studies
which estimate ﬂavonoid content from food consumption
patterns [12].
Another critical issue in experimental design, lacking
in many previous studies, is the need for endpoints which
are valid and reliable markers of cardiovascular health.
Endothelial function is considered one of the best indicators
of vascular health, and dysfunction can be viewed as the
common pathway between coronary risk factors and the
development of atherosclerosis [13–17]. Measurement of
brachial artery dilatation after ﬂow-mediated dilation has
beenthe standard method forassessing endothelialfunction,
but in recent years an equally reliable, but less operator-
dependent, non-invasive test for endothelial function has
been developed for use in clinical research [18–21].
Studies using nutritional supplements with precise
amounts of speciﬁc ﬂavonoids,and which measure eﬀectson
a robust marker of cardiovascular health, such as endothelial
function, are sparse, and results highly variable [21, 22].
Two studies serve as examples: Hale et al. found no beneﬁt
on endothelial function after 2 weeks of supplementation
with the soy ﬂavonoid genistein in a group of 29 healthy
postmenopausal women [23]. Engler et al. found that2 Evidence-Based Complementary and Alternative Medicine
a ﬂavonoid-rich dark chocolate (213mg procyanidins, 46mg
epicatechin) improved endothelial function as compared
to a low-ﬂavonoid chocolate [24]. These discrepant results
highlight the need for more well-designed trials using
diﬀerent ﬂavonoid compounds and quantities.
Studies which use commercially manufactured supple-
ments have an additional beneﬁt to the consumer interested
in distinguishing among the numerous botanical, holistic
products available to them, all claiming salutary eﬀects.
Whileproofofaspeciﬁcbeneﬁcialphysiologiceﬀectdoesnot
translate into evidence for better health or disease reduction,
the vast majority of such products in the marketplace have
not been evaluated in a single scientiﬁcally reputable study.
In an eﬀort to address these issues we performed a
study using a supplement, OPC-3 (nutraMetrix, Division of
Market America, Inc.), consisting of oligomeric proantho-
cyanidins, anthocyanins and other phenolic acids derived
from grape seed, pine bark, bilberry, citrus and red wine
extracts, to determine eﬀects on endothelial function in a
group of healthy volunteers.
2.Subjectsand Methods
Twenty-ﬁve participants were recruited from the employee
populationofthehospitalandrelatedclinics.Allparticipants
were at least 18 years of age, in relatively good health, and
takingnomedicationknowntoimpacttheoutcomeparame-
tersofthestudy. Potentialenrolleeswere excludedforhistory
of: coronary artery disease, cerebrovascular disease, heart
failure, diabetes, renal impairment, uncontrolled hyperten-
sion, untreated or clinically evident thyroid disease, tobacco
use or pregnancy or breastfeeding. Female participants also
were required to use eﬀective birth control during the study.
Participants also were instructed not to change their routine
diet, exercise or weight while in the study. The project
was approved by Carolinas Medical Center’s Institutional
Review Board (IRB), and all participants signed an approved
informed consent document.
Using a computer-generated list, each participant was
assignedtoreceiveinrandomsequenceonefour-weekcourse
each of the supplemental intervention and placebo. Thus
each participant served as his or her own control. A 2-week
wash-out period separated the two study periods. The active
agent and placebo were provided as powders in identical-
looking, sealed foil envelopes.Participants were instructed to
consumethe contentsofone envelope,dissolved in 120ml of
tap water, once daily.
Each dose of the OPC-3 supplement formulation used
in this study provided 250mg of total dried extracts derived
from the sources listed above. A base of inactive ingredients,
including fructose, glucose, citric acid, potassium bicarbon-
ate, silica, calcium sulfate and pectin, contributed to the
tonicity of the solution once water was added, acted as a
pH buﬀer, and covered the bitter and astringent tastes of
the extracts to improve the uniformity of powder blending.
Theplacebowascomprisedoffructose,citricacid,potassium
bicarbonate, maltodextrin, silica, calciumsulfate, apple ﬁber,
FD&C Red #40 and FD&C Blue #1.
The primary study outcome was degree of deterioration
in endothelial function following a high-fat meal. The
endothelialfunctionparameterusedinthisstudyiscalledthe
reactive hyperemia peripheral arterial tonometry (RH-PAT)
index. RH-PAT is a noninvasive technique utilizing ﬁnger
plethysmography to measure pulse volume changes in a digit
after stimulating increased blood ﬂow to the digit, termed
reactive hyperemia. The change in digital pulse volume
during reactive hyperemia relative to baseline is termed
the RH-PAT index (see Figure 1). Assessment of endothelial
function with RH-PAT methodology has been validated in
several previous studies using the same equipment and pro-
tocol used in the current study [18–20]. The measurement
equipment used for this purpose (Endo-PAT2000, Itamar
Medical Ltd, Caesarea, Israel) comprises a ﬁnger probe to
assess digital volume changes accompanying pulse waves. A
blood pressure cuﬀ was placed on one upper arm (study
arm) while the other arm served as a control (control arm).
Probes were placed on each hand for continuous recording
of the PAT signal. After a 10-min equilibration period, the
blood pressure cuﬀwas inﬂated to suprasystolicpressures for
5min.Thecuﬀ was then deﬂated, while PAT recording was
continued for 10min. The data produced were analysed by a
computerin an operator-independent manner. As a measure
of digital pulse volume, the RH-PAT index was calculated as
the ratio of the average amplitude of the PAT signal over
a one-minute time interval, starting one minute after cuﬀ
deﬂation, divided by the average amplitude of the PAT signal
of a 3.5-min time period before cuﬀ inﬂation (baseline).
Subsequently,RH-PAT index valuesfrom thestudy armwere
normalized to the control arm.
The RH-PAT index was measured before starting study
supplement (baseline value) and after completion of each
4-week study period. There was a 2-week wash-out interval
between each 4-week study period to avoid possible residual
eﬀects from the study supplement. On each occasion, the
ﬁrst measurement was made after an overnight fast. The
participant then consumed a high-fat meal, and a second
measurement was made 3 h later. The high-fat meal was
prepared from microwavable commercial available products
and consisted of one cheese omelet (Jimmy Dean Three
Cheese Omelet), one croissant (Jimmy Dean Croissant with
Egg and Cheese), one 4.75 oz serving of French fries (Ore
Ida Extra Crispy Easy Fries) and one bottledwater. This meal
provided a total of 1010 calories, 56 g of total fat, 15g of
saturated fat, and 225mg of cholesterol.
Calculation of the required sample size was based
on expected diﬀerences between the OPC-3 and placebo
treatment groups in the percent decrease in RH-PAT index
after the fatty meal. The only prior studies available for
comparison used an entirely diﬀerent technology to measure
endothelial function, but have shown a diﬀerence in percent
change between a ﬂavonoid supplement and placebo of
between 20 and 50%. For this study, diﬀerences of 60%
(±30%) and 30% (±15%) in the placebo and supplement
treatment groups, respectively, were used for a net between-
groupdiﬀerenceof50%.Assumingstatisticalsigniﬁcance(α)
of 0.05 and a study sample of 20, nominal study power was
estimated at ∼80%.Evidence-Based Complementary and Alternative Medicine 3
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(b)
BASELINE OCCLUSION HYPEREMIA
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Figure 1: (a) Digital pulse volume recording of an individual in
the fasting state showing a steady-state PAT at baseline, complete
disappearance of the signal during cuﬀ inﬂation (occlusion),
followed by an increased PAT signal during recovery (hyperemia
phase). (b) Recording in same individual obtained 3h after a high-
fat meal showing a blunted ﬁnger PAT response during the reactive
hyperemia phase. (c) PAT recording from the contralateral (non-
occluded) ﬁnger.
Baseline characteristics are reported as means and stan-
dard deviations, or frequencies and percents. Tonometry
values and before-after percent changes are expressed as
means and standard deviations. Unpaired t-tests were used
to assess between-group diﬀerences at each baseline and
follow-up interval. Paired t-tests were used to compare the
diﬀerence in percent change between the two study phases.
In all cases, α = 0.05 was used to determine statistical
signiﬁcance, and the SAS System (SAS Institute, Cary, NC)
was used for all analyses.
3.Results
3.1. Study Group Comparisons. Twenty-three of 25 partic-
ipants (mean age 43.4 ± 10.4, 78% female) completed all
evaluations and are included in this report. There were
no smokers. Blood pressures and fasting lipid values were
obtained at the baseline visit to conﬁrm there were no
signiﬁcant dyslipidemias or hypertension, since these risk
factors for vascular disease are associated with abnormal
endothelial function (Table 1). The fasting RH-PAT index at
baseline was 2.13mm (95% CI [1.86, 2.40]) in the active
Table 1: Baseline demographic characteristics of participants.
Participant proﬁle Mean ± SD
Age (years) 43.4 ± 10.4
Female (%) 78
Systolic BP 120.8 ± 10.7
Diastolic BP 75.6 ± 5.9
Total cholesterol 193.3 ± 37.4
Triglycerides 71.6 ± 32.7
HDL-C 48.1 ± 16.4
LDL-C 131.0 ± 36.9
BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol.
phase and 2.04mm (95% CI [1.77, 2.31]) in the placebo
phase, and were not signiﬁcantly diﬀerent (paired t-test P =
.6447). Fasting RH-PAT index values at the end of each 4-
week study phase were also not signiﬁcantly diﬀerent.
3.2. Within-Phase RH-PAT Changes. The percent change in
RH-PAT index values between fasting and post-prandial
states, which is the parameter of endothelial function
deterioration used in this study, are shown in Figure 2.T h e
percent change in the placebo phase at baseline was −10.7
(95% CI [−18.1%, −3.3%]) (P = .0064) and at 4 weeks
was −12.4 (95% CI [−20.5%, −4.3%]) (P = .0045). This
indicates that there was endothelial function deterioration
after the high-fat meal both at baseline and after 4 weeks
of supplementation with the placebo. The percent change
i nt h ea c t i v ep h a s ea tb a s e l i n ew a s−9.9 (95% CI[−21.1%,
−1.2%]) (P = .0772), similar to the placebo phase baseline
deterioration. After 4 weeks of ﬂavonoid supplementation
however there was no statistically signiﬁcant diﬀerence in
percent change between fasting and post-prandial values,
−3.2 (95% CI [−18.0%, 11.7%]) (P = .6633), suggesting
possible protection from the ﬂavonoid.
3.3. Between-Phase RH-PAT Changes. We then took the
percent change in fasting and post-prandial RH-PAT index
values and compared the diﬀerence in those values between
theplaceboand activephases. Atbaseline therewas nodiﬀer-
ence (t-test P = .5892), but after 4 weeks of supplementation
the diﬀerence between placebo and active phases was highly
statistically signiﬁcant (t-test P < 0.0001). Lastly, we assessed
the within-group diﬀerence in percent change from baseline
to 4 weeks and showed no statistically signiﬁcant diﬀerence
in either group (paired t-test P = .7580 for placebo, P =
.4513 for active). The diﬀerence in average percent change
between baseline and 4 weeks in the two study phases was
not statistically signiﬁcant (t-test P = .4492). There were no
signiﬁcant diﬀerences by study phase sequence.
4.Discussion
Flavonoidsareplantsecondarymetaboliteswithawiderange
of biological eﬀects. A protective role against cardiovascular4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Percent changes in RH-PAT index from a fasting state
obtained 3 h after a high-fat meal, at the beginning and end of
each study phase. Solid bars, Baseline (before study supplement);
Hatched bars, After 4 weeks of study supplement; Values shown as
Mean & Standard error.
disease is highly plausible, based on the bulk of epidemio-
logic data as well as experiments in animal models revealing
anti-atherosclerotic eﬀects [1–4]. The epidemiologic studies
however have been quite inconsistent. For example, in an
elderly Dutch population, in which the primary ﬂavonoid
dietary sources were tea, apples and onions, the tertile with
the highest consumption of ﬂavonoids had a 68% lower
risk for cardiovascular disease [7]. Several studies in the
UK and US on the other hand, have demonstrated no
relationship between ﬂavonoid intake and cardiovascular
risk [8–11]. Many plausible explanations have been oﬀered
to explain the discrepancies, all illustrating the extreme
diﬃculty in studying the eﬀect of individual foods and/or
theirconstituentsin epidemiologicstudies,aswell asthebio-
logicalcomplexityofthepolyphenolclassofphytochemicals.
Flavonoids in particular have marked heterogeneity in their
molecular structures, diﬀerences in composition among
various foods, diﬀerences in amount within the same foods
and highly variable bioavailability [12]. Our knowledge
is therefore still too limited to formulate recommenda-
tions for ﬂavonoid intake to reduce risk of cardiovascular
disease.
One way of dealing with this insuﬃcient knowledge is
to issue a general recommendation to increase consumption
of fruits and vegetables. Even though we do not know the
optimal intake or the mechanism by which such a dietary
change might reduce cardiovascular risk, this represents a
reasonable and well-founded eﬀort to improve the nutri-
tional habits of the general population. Changing dietary
habits however is very diﬃcult. Many individuals are likely
to never consume adequate amounts of the foods which
couldreducetheirriskforcardiovasculardisease.Oneoption
is to make up this deﬁcit through supplementation with
the food micronutrients and constituents proven to have
beneﬁcial physiologic vascular eﬀects. Demonstrating such
eﬀects requires the study of speciﬁc commercially available
products, recently shown for example with a juice powder
concentrate[25].Anotheroptionforsomeindividualswould
be to supplement their diet with an amount and mixture of
ﬂavonoidsproventohaveabeneﬁcial eﬀectonavalidmarker
of cardiovascular health.
The majority of studies assessing ﬂavonoid eﬀects on
endothelial function have used whole foods. For example,
studies testing red wine [26, 27], grape juice [28], black tea
[29, 30], soy [31, 32] and cocoa [24], have shown a net
beneﬁcial eﬀect on endothelial function as tested by ﬂow-
mediated dilation of the brachial artery. It would appear
that high ﬂavonoid consumption consistently produces
improvement in endothelial function, but it is uncertain
how much this perception is the result of publication bias
(i.e. studies revealing no beneﬁt are much less likely to be
disseminated in the scientiﬁc literature) and how much this
beneﬁcial eﬀect is dependent on speciﬁc types, mixtures and
amounts of ﬂavonoid compounds. We therefore chose to
study a speciﬁc ﬂavonoid supplement with veriﬁable quality
control in the manufacturing process.
Our results indicate that the ﬂavonoid supplement OPC-
3 can reduce the acute impairment in endothelial function
caused by a high-fat meal. These ﬁndings do not imply
that all the detrimental eﬀects of a high saturated fat
meal are neutralized by taking a ﬂavonoid supplement.
The standardized high-fat meal however is a convenient,
reproducible means to induce endothelial impairment in
healthy volunteers who otherwise have normal endothelial
function as proven by their normal fasting values (RH-PAT
indices from 1.95 to 2.13 in all subgroups). This same model
for inducing endothelial dysfunction in healthy volunteers
has been used and validated in other studies assessing eﬀects
of food on vascular function [33–38].
Our study results add to a growing literature on the
potential beneﬁt of antioxidant phytochemicals providing
a long-term eﬀect on endothelial function, in that the
ﬂavonoid supplement mitigated the adverse eﬀect of a high-
f a tm e a le v e nt h o u g hi tw a sn o ta d m i n i s t e r e di m m e d i a t e l y
p r i o rt ot h em e a l .T h i sﬁ n d i n gi sa l s oc o n s i s t e n tw i t ha
couple of other studies evaluating long-term ingestion of
high-ﬂavonoid foods. Long-term ingestion of a 40% fat diet
impaired endothelial function, but this eﬀect was prevented
with daily ingestion of red wine [38]. Similar results were
reported in coronary heart disease patients after ingestion of
grape juice for two weeks [39].
Nitric oxide (NO) is the primary mediator of
endothelial-dependent vasodilation [40]. There is a good
experimental evidence indicating that the favourable impact
of ﬂavonoid supplementation is due to preservation of NO
bioactivity by facilitating production of NO via endo thelial
NO synthase (eNOS) [41, 42].
There are a couple of limitations to our study. Although
we did demonstrate a statistically signiﬁcant diﬀerence in
endothelial function deterioration between placebo andEvidence-Based Complementary and Alternative Medicine 5
ﬂavonoid groups after 4 weeks of supplementation (the
main endpoint), the diﬀerence in endothelial function
deterioration comparing the baseline and 4-week values
in the ﬂavonoid arm did not reach statistical signiﬁcance.
This was due to the larger than anticipated variability in
deterioration of endothelial function after a high-fat meal.
In retrospect, since all of our subjects were free from major
cardiac risk factors, a high degree of resilience to a high fat
load in some individuals is not surprising. On the other
hand, in spite of the healthy population our high-fat meal
produceda statistically signiﬁcant deteriorationcompared to
fasting in the placebo group both at their baseline evaluation
and after 4 weeks of supplementation. The same response
wasdemonstratedintheﬂavonoidgroupatbaseline.Inother
words, the only group which did not show a deterioration
of endothelial function was the ﬂavonoid group after 4
weeks of supplementation. Thus we doubt that the lack
of statistical diﬀerence in one of our endpoints invalidates
the conclusion that the ﬂavonoid supplement mitigated the
expected endothelial function deterioration.
The other limitation noted is that we did not make a
systematic eﬀort to control for menstrual cycle eﬀects on
endothelial function. Although this factor did not appear to
impact our results there is literature indicating that baseline
endothelial-dependent vasodilatation is slightly larger in the
follicular and luteal phases of the cycle compared to the
menstrual phase [43]. Eﬀects of the menstrual cycle phase
on vasodilatory response to a high-fat meal has not been
speciﬁcally studied.
In conclusion, we have shown that a high-fat meal
on average causes a temporary deterioration in endothelial
function, consistent with other published studies. In healthy
volunteers 4 weeks of supplementation with a ﬂavonoid
supplement signiﬁcantly blunted this deterioration, com-
pared to the placebo, suggesting that this ﬂavonoid sup-
plementation has a beneﬁcial eﬀect on vascular function
in at least certain populations. Whether similar protection
of endothelial function would occur in higher risk groups
(e.g., those with risk factors for cardiovascular disease such
as hypercholesterolemia or diabetes) needs to be studied.
The impact of other mitigating factors, such as background
consumption of fruits and vegetables, or variable ﬂavonoid
intake, also needs to be addressed in future research.
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